Literature DB >> 21376308

Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

Hui-Hui Ma1, Judy Ziegler, Cuiling Li, Antonia Sepulveda, Ahmed Bedeir, Jennifer Grandis, Suzanne Lentzsch, Markus Y Mapara.   

Abstract

The aim of this study was to delineate the temporal and spatial sequence of STAT1 and STAT3 activation during development of GVHD following fully Major Histocompatibility Complex (MHC)-mismatched allogeneic Bone Marrow Transplantation (BMT). Activation of inflammatory signaling pathways in GVHD target organs was assessed by western blotting, phospho-flow cytometry and electromobility shift assays (EMSA). Development of GVHD was associated with significant expansion of phospho[p]-STAT1 and p-STAT3 expressing CD4(+) T cells and CD8(+) T cells. GVHD-specific STAT3/STAT1 activation preceded activation of Nuclear Factor-κB (NF-κB) and Mitogen Activated Protein Kinase (MAPK) and was associated with subsequent induction of STAT1 or STAT3-dependent inflammatory gene-expression programs (e.g. expression of IRF-1, SOCS1, IL-17). Our studies may help to establish a functional hierarchy of the signaling events leading to the development of GVHD and could be helpful in designing new molecularly targeted treatment approaches for GVHD.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376308      PMCID: PMC3061826          DOI: 10.1016/j.cellimm.2011.01.008

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  39 in total

1.  STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model.

Authors:  Vedran Radojcic; Maria A Pletneva; Hung-Rong Yen; Sanja Ivcevic; Angela Panoskaltsis-Mortari; Anita C Gilliam; Charles G Drake; Bruce R Blazar; Leo Luznik
Journal:  J Immunol       Date:  2009-12-07       Impact factor: 5.422

2.  Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.

Authors:  B Nikolic; S Lee; R T Bronson; M J Grusby; M Sykes
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

3.  In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations.

Authors:  Michael J Carlson; Michelle L West; James M Coghill; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

4.  Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.

Authors:  Tangsheng Yi; Dongchang Zhao; Chia-Lei Lin; Chunyan Zhang; Ying Chen; Ivan Todorov; Thomas LeBon; Fouad Kandeel; Stephen Forman; Defu Zeng
Journal:  Blood       Date:  2008-07-02       Impact factor: 22.113

5.  IL-17 contributes to CD4-mediated graft-versus-host disease.

Authors:  Lucy W Kappel; Gabrielle L Goldberg; Christopher G King; David Y Suh; Odette M Smith; Cassandra Ligh; Amanda M Holland; Jeremy Grubin; Nicholas M Mark; Chen Liu; Yoichiro Iwakura; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

6.  STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease.

Authors:  Sydney X Lu; Onder Alpdogan; Janine Lin; Robert Balderas; Roberto Campos-Gonzalez; Xiao Wang; Guo-Jian Gao; David Suh; Christopher King; Melanie Chow; Odette M Smith; Vanessa M Hubbard; Johanne L Bautista; Javier Cabrera-Perez; Johannes L Zakrzewski; Adam A Kochman; Andrew Chow; Gregoire Altan-Bonnet; Marcel R M van den Brink
Journal:  Blood       Date:  2008-10-06       Impact factor: 22.113

7.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

Authors:  Xiao Chen; Sanja Vodanovic-Jankovic; Bryon Johnson; Melissa Keller; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

8.  T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease.

Authors:  Cristina Iclozan; Yu Yu; Chen Liu; Yaming Liang; Tangsheng Yi; Claudio Anasetti; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-02       Impact factor: 5.742

9.  Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.

Authors:  Yaping Sun; Y Eugene Chin; Elizabeth Weisiger; Chelsea Malter; Isao Tawara; Tomomi Toubai; Erin Gatza; Paolo Mascagni; Charles A Dinarello; Pavan Reddy
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

Review 10.  Transcriptional regulation of Th17 cell differentiation.

Authors:  Ivaylo I Ivanov; Liang Zhou; Dan R Littman
Journal:  Semin Immunol       Date:  2007-11-28       Impact factor: 11.130

View more
  14 in total

Review 1.  Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.

Authors:  Cameron McDonald-Hyman; Laurence A Turka; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2015-03-25       Impact factor: 17.956

2.  The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.

Authors:  Dawn K Reichenbach; Vincent Schwarze; Benjamin M Matta; Victor Tkachev; Elisabeth Lieberknecht; Quan Liu; Brent H Koehn; Dietmar Pfeifer; Patricia A Taylor; Gabriele Prinz; Heide Dierbach; Natalie Stickel; Yvonne Beck; Max Warncke; Tobias Junt; Annette Schmitt-Graeff; Susumu Nakae; Marie Follo; Tobias Wertheimer; Lukas Schwab; Jason Devlin; Simon C Watkins; Justus Duyster; James L M Ferrara; Heth R Turnquist; Robert Zeiser; Bruce R Blazar
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

3.  IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jin Yan; Eva Pizzoferrato; John H Yim
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

4.  Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.

Authors:  Christian M Capitini; Nicole M Nasholm; Christopher D Chien; Shannon M Larabee; Haiying Qin; Young K Song; Peter J Klover; Lothar Hennighausen; Javed Khan; Terry J Fry
Journal:  Blood       Date:  2014-07-25       Impact factor: 22.113

5.  The role of chemokines in mediating graft versus host disease: opportunities for novel therapeutics.

Authors:  Marina G M Castor; Vanessa Pinho; Mauro M Teixeira
Journal:  Front Pharmacol       Date:  2012-02-24       Impact factor: 5.810

Review 6.  Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies.

Authors:  Nancy Y Villa; Masmudur M Rahman; Grant McFadden; Christopher R Cogle
Journal:  Viruses       Date:  2016-03-22       Impact factor: 5.048

7.  Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

Authors:  Huijie Jia; Tiesuo Zhao; Yinghua Ji; Xiaolong Jia; Wenjing Ren; Chen Li; Minming Li; Yali Xiao; Hui Wang; Kailin Xu
Journal:  Cell Death Dis       Date:  2016-12-01       Impact factor: 8.469

Review 8.  Current data on IL-17 and Th17 cells and implications for graft versus host disease.

Authors:  Marília Normanton; Luciana Cavalheiro Marti
Journal:  Einstein (Sao Paulo)       Date:  2013 Apr-Jun

9.  Therapeutic effects of STAT3 inhibition by nifuroxazide on murine acute graft graft-vs.-host disease: Old drug, new use.

Authors:  Huijie Jia; Jing Cui; Xiaolong Jia; Jingjing Zhao; Yuchen Feng; Peijuan Zhao; Dan Zang; Jian Yu; Tiesuo Zhao; Hui Wang; Kailin Xu
Journal:  Mol Med Rep       Date:  2017-10-19       Impact factor: 2.952

10.  Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD.

Authors:  Kati Hyvärinen; Satu Koskela; Riitta Niittyvuopio; Anne Nihtinen; Liisa Volin; Urpu Salmenniemi; Mervi Putkonen; Ismael Buño; David Gallardo; Maija Itälä-Remes; Jukka Partanen; Jarmo Ritari
Journal:  Front Immunol       Date:  2020-02-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.